- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and Tolerability of c-MET Inhibitors in Cancer
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-16
DOI
10.1007/s40264-018-0780-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
- (2018) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
- (2018) Robert J. Motzer et al. BRITISH JOURNAL OF CANCER
- A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types
- (2018) Steven Lacy et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer
- (2018) Anthony B. El-Khoueiry et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
- (2018) Takeshi Hirota et al. CLINICAL PHARMACOKINETICS
- Recent advances in the discovery of small molecule c-Met Kinase inhibitors
- (2018) Palak K. Parikh et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
- (2018) Mohamed Bouattour et al. HEPATOLOGY
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
- (2018) Benjamin J. Solomon et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR- Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study
- (2018) Giorgio V. Scagliotti et al. Journal of Thoracic Oncology
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
- (2018) Yazhuo Zhang et al. Molecular Cancer
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
- (2018) Mary Lou Affronti et al. ONCOLOGIST
- Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma
- (2018) Alberto Broniscer et al. PEDIATRIC BLOOD & CANCER
- Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
- (2018) Bruce W. Konicek et al. Oncotarget
- First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
- (2018) John H. Strickler et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours
- (2017) Jordi Rodon et al. EUROPEAN JOURNAL OF CANCER
- Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
- (2017) Shumei Kato et al. INVESTIGATIONAL NEW DRUGS
- A Phase 1 study evaluating AMG 337 in Asian patients with advanced solid tumors†
- (2017) Hirofumi Yasui et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
- (2017) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ONCOLOGY
- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study
- (2017) Yael P. Mossé et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
- (2017) J. Goldman et al. Journal of Thoracic Oncology
- MA 12.02 Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI
- (2017) G. Chang et al. Journal of Thoracic Oncology
- Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2017) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Editor’s Highlight: Placental Disposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon
- (2017) Gaby A.M. Eliesen et al. TOXICOLOGICAL SCIENCES
- Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3
- (2017) Toshihiro Sato et al. XENOBIOTICA
- A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
- (2017) Natasha B. Leighl et al. Oncotarget
- Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
- (2017) Melissa Bersanelli et al. Therapeutic Advances in Medical Oncology
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
- (2017) Manish A. Shah et al. JAMA Oncology
- Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults
- (2016) Linh Nguyen et al. ANTI-CANCER DRUGS
- Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
- (2016) Sara M. Tolaney et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2016) Thomas C.C. Yau et al. CLINICAL CANCER RESEARCH
- Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer
- (2016) E. Wang et al. CLINICAL CANCER RESEARCH
- A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
- (2016) Lee S. Rosen et al. CLINICAL CANCER RESEARCH
- Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer
- (2016) Weiwei Tan et al. CLINICAL DRUG INVESTIGATION
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
- (2016) Steven A. Lacy et al. CLINICAL PHARMACOKINETICS
- Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study
- (2016) Pasi A. Jänne et al. Journal of Thoracic Oncology
- A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
- (2016) Tony Shu Kam Mok et al. Journal of Thoracic Oncology
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma
- (2016) V Finisguerra et al. ONCOGENE
- High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells
- (2016) Hidenori Fujita et al. PLoS One
- Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
- (2015) A. Hultberg et al. CANCER RESEARCH
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
- (2014) E. Van Cutsem et al. CLINICAL CANCER RESEARCH
- MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure
- (2014) Carla Boccaccio et al. CURRENT OPINION IN CELL BIOLOGY
- c-MET Inhibitors in the Treatment of Lung Cancer
- (2014) Joanna Goździk-Spychalska et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects
- (2014) Huiping Xu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Severe Photosensitivity Dermatitis Caused by Crizotinib
- (2014) Matthew G. Oser et al. Journal of Thoracic Oncology
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
- (2014) Maria E. Cabanillas et al. THYROID
- Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects
- (2014) Theodore R. Johnson et al. XENOBIOTICA
- Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
- (2013) Seng Chuan Tang et al. INTERNATIONAL JOURNAL OF CANCER
- MET As a Possible Target for Non–Small-Cell Lung Cancer
- (2013) Ahad A. Sadiq et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivantinib—a cytotoxic drug in MET inhibitor's clothes?
- (2013) Paolo Michieli et al. Nature Reviews Clinical Oncology
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
- (2013) Holly M. Nguyen et al. PLoS One
- In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
- (2013) Frauke Bentzien et al. THYROID
- c-Met inhibitors
- (2013) Anum Mughal et al. Infectious Agents and Cancer
- breast cancer, early stage
- (2012) T. S. K. Mok et al. ANNALS OF ONCOLOGY
- Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
- (2012) Wen-jing Zhou et al. BRITISH JOURNAL OF PHARMACOLOGY
- A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
- (2012) Geoffrey I. Shapiro et al. INVESTIGATIONAL NEW DRUGS
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
- (2012) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Abstract 1673: A pharmacokinetics/pharmacodynamics evaluation of the concentration-QTc relationship of PF-02341066 (PF-1066), an ALK and c-MET/HGFR dual inhibitor administered orally to patients with advanced cancer
- (2011) Dana Nickens et al. CANCER RESEARCH
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs
- (2011) Neelesh Sharma et al. Therapeutic Advances in Medical Oncology
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
- (2010) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation
- (2010) R. S. Foti et al. DRUG METABOLISM AND DISPOSITION
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now